健择联合顺铂化疗对非小细胞肺癌患者外周血CD4~+CD25~+Foxp3~+调节T细胞的影响

目的探讨健择联合顺铂对非小细胞肺癌患者免疫耐受的调控作用。方法38例经病理学或细胞学确诊的NSCLC患者,采用健择、顺铂联合化疗方案,应用流式细胞仪检测化疗前后外周血CD4+CD25+Foxp3+调节T细胞(Treg)占CD4+T细胞的百分率。结果化疗前NSCLC患者外周血CD4+CD25+Foxp3+调节T细胞(Treg)占CD4+T细胞的比率明显高于健康对照组(P<0.05);化疗后NSCLC患者外周血CD4+CD25+Foxp3+调节T细胞(Treg)占CD4+T细胞的百分率较化疗前显著降低(P<0.05);但鳞癌、腺癌及腺鳞癌3组间化疗前、化疗后各项指标之间差异无统计学意义(P>0.05)。结论健择联合顺铂化疗可调控晚期非小细胞肺癌机体的肿瘤免疫耐受,改善患者的免疫功能。

Changes of the CD4+ CD25+ Foxp3+ Treg Cells in Peripheral Blood in Patients with NSCLC with Gemzar and Cisplatin Regimen

Objective 　To investgate the effect on immune function of patient s with non2small cell lung cancer (NSCLC) t reated with gemcitabine and cisplatin regimen. Methods 　The prevalence of CD4 + CD25 + Foxp3 + T regulatory ( Treg) cells in peripheral blood in 38 patient s with NSCLC , t reated with gemcitabine plus cisplatin chemotherapy regimen , was detected by flow cytomet ry. Results 　The percent2 age of CD4 + CD25 + Foxp3 + Treg cells in peripheral blood of the patient s with NSCLC pre2chemotherapy was significantly higher than that in healthy doners ;compared with pre2chemotherapy , the percentage of CD4 + CD25 + Foxp3 + Treg cells in peripheral blood was significantly decreased in post2chemotherapy pa2 tient s ( P < 0. 05) ; there were no significant differences observed among squamous cell carcinoma , adeno2 carcinoma and adenosquamocarcinoma ( P > 0. 05) . Conclusion 　Gemcitabine plus cisplatin chemotherapy can improve the immune2tolerance in advanced non2small cell lung cancer patient s.